These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37042260)

  • 1. Machine Learning Identifies Plasma Metabolites Associated With Heart Failure in Underrepresented Populations With the
    Park JK; Petrazzini BO; Saha A; Vaid A; Vy HMT; Márquez-Luna C; Chan L; Nadkarni GN; Do R
    J Am Heart Assoc; 2023 Apr; 12(8):e027736. PubMed ID: 37042260
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry.
    Parker MM; Damrauer SM; Tcheandjieu C; Erbe D; Aldinc E; Hawkins PN; Gillmore JD; Hull LE; Lynch JA; Joseph J; Ticau S; Flynn-Carroll AO; Deaton AM; Ward LD; Assimes TL; Tsao PS; Chang KM; Rader DJ; Fitzgerald K; Vaishnaw AK; Hinkle G; Nioi P
    Sci Rep; 2021 Jun; 11(1):11645. PubMed ID: 34079032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry.
    Damrauer SM; Chaudhary K; Cho JH; Liang LW; Argulian E; Chan L; Dobbyn A; Guerraty MA; Judy R; Kay J; Kember RL; Levin MG; Saha A; Van Vleck T; Verma SS; Weaver J; Abul-Husn NS; Baras A; Chirinos JA; Drachman B; Kenny EE; Loos RJF; Narula J; Overton J; Reid J; Ritchie M; Sirugo G; Nadkarni G; Rader DJ; Do R
    JAMA; 2019 Dec; 322(22):2191-2202. PubMed ID: 31821430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy.
    Huda A; Castaño A; Niyogi A; Schumacher J; Stewart M; Bruno M; Hu M; Ahmad FS; Deo RC; Shah SJ
    Nat Commun; 2021 May; 12(1):2725. PubMed ID: 33976166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
    Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
    Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
    Penchala SC; Connelly S; Wang Y; Park MS; Zhao L; Baranczak A; Rappley I; Vogel H; Liedtke M; Witteles RM; Powers ET; Reixach N; Chan WK; Wilson IA; Kelly JW; Graef IA; Alhamadsheh MM
    Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9992-7. PubMed ID: 23716704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis.
    Thenappan T; Fedson S; Rich J; Murks C; Husain A; Pogoriler J; Anderson AS
    Amyloid; 2014 Jun; 21(2):120-3. PubMed ID: 24818650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An additive destabilising effect of compound T60I and V122I substitutions in ATTRv amyloidosis.
    Prokaeva T; Klimtchuk ES; Feschenko P; Spencer B; Cui H; Burks EJ; Aslebagh R; Muneeruddin K; Shaffer SA; Varghese E; Berk JL; Connors LH
    Amyloid; 2023 Jun; 30(2):141-152. PubMed ID: 36286264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
    Madhani A; Sabogal N; Massillon D; Paul LD; Rodriguez C; Fine D; Helmke S; Winburn M; Kurian D; Raiszadeh F; Teruya S; Cohn E; Einstein AJ; Miller EJ; Connors LH; Maurer MS; Ruberg FL
    J Am Heart Assoc; 2023 Aug; 12(15):e028973. PubMed ID: 37486082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis.
    Connors LH; Prokaeva T; Lim A; Théberge R; Falk RH; Doros G; Berg A; Costello CE; O'Hara C; Seldin DC; Skinner M
    Am Heart J; 2009 Oct; 158(4):607-14. PubMed ID: 19781421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. V122I Transthyretin Cardiomyopathy: An Opportunity to Build Trust and Resolve Disparities.
    Sher T; Velarde GP; Gertz MA
    J Am Coll Cardiol; 2020 Jul; 76(1):93-95. PubMed ID: 32616166
    [No Abstract]   [Full Text] [Related]  

  • 12. Understanding Changes in Functional Capacity After TTR Stabilization in Patients With Transthyretin Cardiac Amyloidosis.
    Cuddy SAM
    Circ Heart Fail; 2022 Jul; 15(7):e009387. PubMed ID: 35766044
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
    Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
    JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low Prevalence of Clinically Apparent Cardiac Amyloidosis Among Carriers of Transthyretin V122I Variant in a Large Electronic Medical Record.
    Agbor-Etang BB; Okafor HE; Farber-Eger EH; Wells QS
    Am J Med; 2021 Feb; 134(2):e98-e100. PubMed ID: 32866461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac Amyloidosis.
    Dungu JN; Papadopoulou SA; Wykes K; Mahmood I; Marshall J; Valencia O; Fontana M; Whelan CJ; Gillmore JD; Hawkins PN; Anderson LJ
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Disease and Mortality in Black Women Carrying the Amyloidogenic V122I Transthyretin Gene Variant.
    Haring B; Hunt RP; Shadyab AH; Eaton C; Kaplan R; Martin LW; Panjrath G; Kuller LH; Assimes T; Kooperberg C; Wassertheil-Smoller S
    JACC Heart Fail; 2023 Sep; 11(9):1189-1199. PubMed ID: 36930136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
    Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
    Skrahina V; Grittner U; Beetz C; Skripuletz T; Juenemann M; Krämer HH; Hahn K; Rieth A; Schaechinger V; Patten M; Tanislav C; Achenbach S; Assmus B; Knebel F; Gingele S; Skrahin A; Hartkamp J; Förster TM; Roesner S; Pereira C; Rolfs A
    Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
    Ruberg FL; Blaner WS; Chiuzan C; Connors LH; Einstein AJ; Fine D; Helmke S; Kurian D; Pandey S; Raiszadeh F; Rodriguez C; Sabogal N; Teruya S; Winburn M; Chung WK; Cohn E; Miller EJ; Kelly JW; Maurer MS
    J Am Heart Assoc; 2023 Apr; 12(8):e028534. PubMed ID: 37066788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Transthyretin-related amyloidotic cardiomyopathy: looking for the etiological treatment].
    Longhi S; Gagliardi C; Milandri A; Manuzzi L; Rapezzi C
    G Ital Cardiol (Rome); 2014 May; 15(5):293-300. PubMed ID: 25002169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.